Asthma,Tuberculosis,Cystic Fibrosis, Non-Small Cell Lung Cancer,Respiratory Tract, Respiratory Distress Syndrome, Chronic Obstructive Pulmonary Disease (COPD), Pneumonia, Status Asthmaticus,Respiratory Syncytial Virus(RSV), Portable Oxygen Concentrator, Home Liquid Oxygen, Emphysema, Pulmonary Arterial Hypertension (PAH)...
October 31, 2007 - Theravance, Inc. (NASDAQ: THRX) announced that GSK has initiated a Phase 2 clinical study of GSK961081, an investigational bifunctional muscarinic antagonist-beta2 agonist compound for the treatment of chronic obstructive pulmonary disease (COPD)... 
Theravance's Press Release -
&btnG=Rechercher&cx=009827733776089099007:ofxjf6zyc-k){kind=link}